Navigation Links
Enrollment Completed in Regeneron and Bayer HealthCare Phase 3 Studies of VEGF Trap-Eye in Neovascular Age-Related Macular Degeneration (Wet AMD)
Date:9/14/2009

the proportion of patients who gained at least 15 letters of vision at week 52.

About VEGF Trap-Eye

Vascular Endothelial Growth Factor (VEGF) is a naturally occurring protein in the body whose normal role is to trigger the formation of new blood vessels (angiogenesis) to support the growth of the body's tissues and organs. It has also been associated with the abnormal growth and fragility of new blood vessels in the eye, which lead to the development of wet AMD. VEGF Trap-Eye is a fully human, soluble VEGF receptor fusion protein that binds all forms of VEGF-A along with the related placental growth factor (PIGF). Investigational VEGF Trap-Eye is a specific blocker of VEGF-A and PlGF that has been demonstrated in preclinical models to bind these growth factors with greater affinity than their natural receptors. Blockade of VEGF can prevent abnormal blood vessel formation as well as vascular leak and has proven beneficial in the treatment of wet AMD.

VEGF Trap-Eye is also in Phase 3 development for the treatment of Central Retinal Vein Occlusion (CRVO), another cause of blindness. The COPERNICUS (COntrolled Phase 3 Evaluation of Repeated iNtravitreal administration of VEGF Trap-Eye In Central retinal vein occlusion: Utility and Safety) study is being led by Regeneron and the GALILEO (General Assessment Limiting InfiLtration of Exudates in central retinal vein Occlusion with VEGF Trap-Eye) study is being led by Bayer HealthCare. Patients in both studies will receive six monthly intravitreal injections of either VEGF Trap-Eye at a dose of 2 mg or sham control injections. The primary endpoint of both studies is improvement in visual acuity versus baseline after six months of treatment. At the end of the initial six months, patients will be dosed on a PRN (as needed) basis for another six months. All patients will be eligible for rescue laser treatment. Initial data from the program are anticipated in early
'/>"/>

SOURCE Regeneron Pharmaceuticals, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5

Related medicine technology :

1. R-Tech Ueno Completes Subject Enrollment in Phase 2 Clinical Study of 0.15% UF-021
2. Roskamp Institute Announces Enrollment of First Students to Participate in its Innovative Research Doctorate Program
3. MacroGenics and Lilly Achieve Targeted Patient Enrollment in PROTEGE, a Global Phase 2/3 Clinical Trial of Teplizumab in Type 1 Diabetes
4. Osteotech Completes Enrollment for DuraTech(TM) BioRegeneration Matrix Clinical Trial
5. Enrollment in Delcaths Pivotal Phase III Metastatic Melanoma Clinical Trial Achieves Seventy-Five Percent Accrual
6. Novavax Completes Enrollment of Its Second Phase II Seasonal Influenza VLP Vaccine Clinical Trial
7. TargeGen Announces Successful Completion of Patient Enrollment in Clinical Trial of JAK2 Inhibitor TG101348 in Myelofibrosis Patients and Scheduled Presentation of Preliminary Trial Data at EHA Conference in Berlin
8. InspireMD Announces the Enrollment of the 1st Patient in the MGuard iMOS Registry, the Registry Will Enroll 1000 Patients
9. Peregrine Pharmaceuticals Completes Patient Enrollment in its Phase II Trial of Bavituximab Plus Docetaxel in Breast Cancer Patients
10. Video: ev3 Inc. Announces First Patient Enrollments in DEFINITIVE LE Post-Market Study
11. Intarcia Therapeutics, Inc. Announces Completion of Enrollment of ITCA 650 Phase 1b Study for the Treatment of Type 2 Diabetes
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/19/2014)... Mass. , Dec. 18, 2014  Decision Resources ... the United States will increase to ... will be primarily driven by expansion in the large ... energy devices will be increasingly adopted due to the ... Other key findings from Decision Resources Group,s ...
(Date:12/19/2014)... -- Baptist Health Lexington is the first facility in ... Fibrillation with Electrophysiology Services (EPS) Accreditation status from the Society ... the most common cardiac arrhythmia and has become recognized as ... stroke and possible death. More than 5 million patients in ... and the numbers are rapidly increasing as the population ages. ...
(Date:12/19/2014)... and LYON, France , Dec. 19, ... LLY ) and Adocia (Euronext Paris: FR0011184241 – ADOC) ... an ultra-rapid insulin, known as BioChaperone Lispro, for treatment ... BioChaperone Lispro relies on Adocia,s proprietary BioChaperone® technology and ... and Adocia will develop BioChaperone Lispro with the goal ...
Breaking Medicine Technology:U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 2U.S. Laparoscopic Device Market Will Reach Over $4.3 Billion by 2023 3Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 2Baptist Health Lexington First in the Nation to Receive Atrial Fibrillation with EPS Accreditation 3Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 2Lilly and Adocia Announce Alliance to Co-Develop Ultra-Rapid Insulin Based on BioChaperone Technology 3
... SARcode Corporation presented data today for their lead investigational ... trial, subjects receiving SAR 1118 demonstrated a reduction in ... as compared to placebo. These data were part of ... Vision and Ophthalmology (ARVO) Annual Meeting held in Fort ...
... 3, 2011 At the Board of Directors meeting held ... per share. The dividend is payable on June 15, 2011 ... About Sigma-Aldrich: Sigma-Aldrich is a leading ... to Improve the Quality of Life. Its chemical and biochemical ...
Cached Medicine Technology:SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 2SAR 1118 Demonstrates Encouraging Results in Phase 2 Study of Dry Eye Disease 3
(Date:12/19/2014)... Cranbury, NJ (PRWEB) December 19, 2014 ... of Inside Patient Care: Pharmacy & Clinics™, an ... entire healthcare team treating and caring for patients ... As primary care expands to provide optimal access ... Clinics™ offers a forum for the team treating ...
(Date:12/19/2014)... (PRWEB) December 19, 2014 ... the diagnostic, personalized medicine, healthcare information technology, and ... the position of Chief Operating Officer. The announcement ... Partners, marked by a strengthened presence in Boston ... , "Leslie lives and breathes the client experience," ...
(Date:12/19/2014)... in good shape seems to reduce your risk of high ... more than 57,000 Americans, including more than 35,000 with high ... Those in the poorest shape had a more than ... start of the study, compared to a 50 percent chance ... more than 8,000 people diagnosed with high blood pressure during ...
(Date:12/19/2014)... 18, 2014 (HealthDay News) -- Traveling through the same ... virus to three others within a four-hour time span, ... new report shows. "The exposures in this report ... than an international terminal, highlighting the fact that measles ... Vega, an infectious disease specialist at the U.S. Centers ...
(Date:12/17/2014)... 17, 2014 Unidesk Corporation today ... (ACOM), which welcomed its inaugural class in August ... to seamlessly support bring your own device (BYOD) ... – experience. The solution, comprised of Citrix ... Dell server and storage infrastructure and ...
Breaking Medicine News(10 mins):Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 2Health News:The Transformation of Retail Pharmacies into a Healthcare Delivery Center 3Health News:Slone Partners Promotes Leslie Loveless to Chief Operating Officer 2Health News:Being Fit Keeps Blood Pressure in Check 2Health News:Arriving Now at Gate 42: Measles 2Health News:Arriving Now at Gate 42: Measles 3Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 2Health News:Alabama College of Osteopathic Medicine Deploys Desktop Virtualization Solution from Citrix, Dell and Unidesk 3
... , WASHINGTON , Feb. 14 Following is the ... http://www.newscom.com/cgi-bin/prnh/20090226/CENSUSLOGO ) , SUNDAY, FEBRUARY 14 : ... for the 14th day of Black History Month.  Dr. Daniel Hale ... end of the 19th century.  He founded Provident Hospital, the nation,s first ...
... , AUSTIN, Texas , Feb. 13 ... are sources of satisfaction for many gardeners. For allergy sufferers, though, ... , Pollen from trees, shrub and grasses can cause an onslaught ... cases, an asthma attack. , But sensitive people can take a ...
... improve on your personal best , SATURDAY, Feb. 13 (HealthDay News) ... you can learn from them if you want to improve your ... us to push the boundaries of human potential. As I tell ... mimic the strategies of those at the top," Chris Sebelski, an ...
... , ... largest provider of Microsoft certifications in North America, is proud to announce that CED Solutions ... for the first 500 applicants starting today. Students will also obtain a licensed copy ... ...
... ... the President,s proposed budget. , ... (PRWEB) February 13, 2010 -- President Obama presented America and Congress with his new budget ... presented throughout its 192 pages. Mountainside Addiction Treatment Center has scrubbed through the budget ...
... , , WASHINGTON , Feb. 12 ... pleased to announce that its contract with the U.S. Department of ... 30, 2010 . , "Since HITSP,s formation in 2005, the Panel ... electronic health records," said Fran Schrotter , HITSP project director ...
Cached Medicine News:Health News:U.S. Census Bureau Black History Month Feature for Feb. 14 2Health News:Avoid Allergens to Reap the Rewards of Gardening 2Health News:Avoid Allergens to Reap the Rewards of Gardening 3Health News:Train Like an Olympian: Here's How 2Health News:CED Solutions Offers Free 3-Day Technical Windows 7 Certification Course for Unemployed Individuals 2Health News:New York and Connecticut Drug Rehab Center Mountainside Weighs In on Latest White House Budget 2Health News:New York and Connecticut Drug Rehab Center Mountainside Weighs In on Latest White House Budget 3Health News:HITSP Contract With U.S. HHS Extended Through April 2010 2Health News:HITSP Contract With U.S. HHS Extended Through April 2010 3
... is an innovative and efficient inverted ... complements any research facility. Improved mechanics ... offers the TS100 binocular and TS100-F ... comes with a photo port that ...
... color imaging camera system designed for ... performance, megapixel digital cameras provides high-resolution, ... them on a PC via its ... "live" previewing capability is accompanied by ...
... Megapixel color imaging camera system designed ... high performance, megapixel digital cameras provides ... view them on a PC via ... This "live" previewing capability is accompanied ...
... The PM30 is a premium photomicrography system ... photomicrographs of even the most difficult specimens. ... new PM30 system provide solution to the ... to their automatic exposure control, the system ...
Medicine Products: